Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Rectal Neoplasms 1Radiation Injuries 1Multiple Myeloma 1Multiple Chronic Conditions 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Fatigue 1Cognitive Dysfunction 1Carcinoma, Basal Cell 1Breast Neoplasms 1Breast Neoplasm Female 1Brain Neoplasms 1

Interventions

Cyclophosphamide 18Rituximab 10fludarabine 8ibrutinib 6fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Radiotherapy 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Cyclosporine 4Chlorambucil 4Antilymphocyte Serum 4Antigens, CD19 4Valproic Acid 3Sensitivity and Specificity 3Indium 3Immunotherapy, Adoptive 3Busulfan 3Alemtuzumab 3venetoclax 2sargramostim 2obinutuzumab 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 2epratuzumab 2Tacrolimus 2Radioimmunodetection 2Psychiatric Rehabilitation 2Pentostatin 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Lymphocytic, Chronic, B-Cell × Patient Reported Outcome Measures × Clear all
NCT04663100 2023-12-04

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

University of Tennessee

Phase NA Unknown
30 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Multiple Chronic Conditions, Leukemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡